カテゴリ： Allied Market Research, 世界, 医療/バイオ

視神経疾患治療のグローバル市場（2021～2031）：ステロイド療法、免疫調節療法、その他

■ 英語タイトル：Optic Nerve Disorders Treatment Market By Treatment Type (Steroidal Therapy, Immunomodulators therapy, Others), By Indication (Glaucoma, Optic Neuritis, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC094）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC094
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：257
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[視神経疾患治療のグローバル市場（2021～2031）：ステロイド療法、免疫調節療法、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には3,372.46百万ドルであった世界の視神経疾患治療市場規模が2031年には5,247.82百万ドルへ及び、2022年から2031年の間にCAGR 4.5％増加すると推測されています。本調査資料では、視神経疾患治療の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、治療種類別（ステロイド療法、免疫調節療法、その他）分析、疾患別（緑内障、視神経炎、その他）分析、流通チャネル別（病院内薬局、ドラッグストア・小売薬局、オンラインプロバイダー）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、Santen Pharmaceutical Co., Ltd.、AbbVie Inc.、Novartis AG、Bausch Health Companies, Inc.、Merck & Co., Inc.、.Aerie Pharmaceuticals, Inc.、Cipla Ltd、mallinckrodt pharmaceuticals、Pfizer, Inc.、Teva Pharmaceutical Industries Ltd.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の視神経疾患治療市場規模：治療種類別
- ステロイド療法の市場規模
- 免疫調節療法の市場規模
- その他視神経疾患治療の市場規模
・世界の視神経疾患治療市場規模：疾患別
- 緑内障における市場規模
- 視神経炎における市場規模
- その他疾患における市場規模
・世界の視神経疾患治療市場規模：流通チャネル別
- 病院内薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
・世界の視神経疾患治療市場規模：地域別
- 北米の視神経疾患治療市場規模
- ヨーロッパの視神経疾患治療市場規模
- アジア太平洋の視神経疾患治療市場規模
- 中南米/中東・アフリカの視神経疾患治療市場規模
・競争状況
・企業情報

世界の視神経疾患治療市場は、2021年に33億7,246万ドルと評価され、2022年から2031年にかけて年平均成長率4.5%で成長して2031年には52億4,782万ドルに達すると予測されています。

目の視神経は第2脳神経で、視覚のための感覚情報を脳に伝達する働きをします。この神経は、胎児の発育中に前脳の視神経胞から発達します。視神経または脳につながる視神経経路が損傷すると、視力が低下します。
緑内障、視神経萎縮、視神経炎など、さまざまな種類の視神経障害が世界中で流行しています。これらの疾患のほとんどは対症療法で治療されます。治療によって視力が改善することはありませんが、障害によってさらに起こる可能性のある視力低下を防ぐことはできます。

視神経疾患治療市場は、眼疾患に罹患する高齢者人口の増加、革新的技術の発売、医療費の増加、政府支援の強化などにより、予測期間中に大きな市場成長が見込まれると推定されます。加えて、各社の研究開発投資の増加、強力なパイプライン候補の存在、医療インフラ整備への支出の増加などが、市場の成長をさらに促進します。しかし、熟練した専門家の不足が市場成長の妨げになる見通し。一方、公共部門だけでなく民間部門における医療投資の急増は、視神経疾患治療市場に大きな成長機会をもたらすと予想されます。

視神経疾患治療市場は、治療タイプ、疾患、流通チャネル、地域によって区分されます。
治療タイプ別では、市場はステロイド療法、免疫調節剤療法、その他に分類されます。
疾患別では、市場は視神経炎、緑内障、視神経萎縮、その他に分類されます。
流通チャネル別では、病院薬局、ドラッグストア、小売薬局、オンラインプロバイダーに分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

本レポートは、世界の視神経疾患治療市場で事業を展開する主要企業の包括的な分析を提供します。本レポートに掲載されている主要企業には、AbbVie Inc.、Alcon Inc.、Bausch Health Companies, Inc.、Cipla Ltd.、Mallinckrodt pharmaceuticals、Merck & Co., Inc.、Novartis AG、Pfizer, Inc.、参天製薬株式会社、Teva pharmaceutical industries ltd.などがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの視神経疾患治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、有力な視神経疾患治療市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・視神経疾患治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・視神経疾患治療の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
治療タイプ別
ステロイド療法
免疫調節剤療法
その他

疾患別
緑内障
視神経炎
その他

流通チャネル別
病院薬局
ドラッグストア・薬局
オンラインプロバイダー

地域別
・北米
米国
カンダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
参天製薬株式会社
AbbVie Inc.
Novartis AG
Bausch Health Companies, Inc.
Merck & Co., Inc.
.Aerie Pharmaceuticals, Inc.
Cipla Ltd
mallinckrodt pharmaceuticals
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. High threat of substitutes
3.3.4. High threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of optic nerve disorder
3.4.1.2. Growth in geriatric population
3.4.1.3. Increase in technological advancement

3.4.2. Restraints
3.4.2.1. Dearth of skilled professionals

3.4.3. Opportunities
3.4.3.1. Growth potential of emerging economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Steroidal Therapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Immunomodulators therapy
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Glaucoma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Optic Neuritis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: OPTIC NERVE DISORDERS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Treatment Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Treatment Type
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canda
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Treatment Type
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Treatment Type
7.2.5.3.3. Market size and forecast, by Indication
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Treatment Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Treatment Type
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Treatment Type
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Treatment Type
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Treatment Type
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Treatment Type
7.3.5.5.3. Market size and forecast, by Indication
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Treatment Type
7.3.5.6.3. Market size and forecast, by Indication
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Treatment Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Treatment Type
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Treatment Type
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Treatment Type
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Treatment Type
7.4.5.4.3. Market size and forecast, by Indication
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Treatment Type
7.4.5.5.3. Market size and forecast, by Indication
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Treatment Type
7.4.5.6.3. Market size and forecast, by Indication
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Treatment Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Treatment Type
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Treatment Type
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Treatment Type
7.5.5.3.3. Market size and forecast, by Indication
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Treatment Type
7.5.5.4.3. Market size and forecast, by Indication
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Santen Pharmaceutical Co., Ltd.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. AbbVie Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Pfizer, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Bausch Health Companies, Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Teva Pharmaceutical Industries Ltd.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. mallinckrodt pharmaceuticals
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Merck & Co., Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. .Aerie Pharmaceuticals, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Cipla Ltd
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. OPTIC NERVE DISORDERS TREATMENT MARKET FOR STEROIDAL THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. OPTIC NERVE DISORDERS TREATMENT MARKET FOR IMMUNOMODULATORS THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. OPTIC NERVE DISORDERS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. OPTIC NERVE DISORDERS TREATMENT MARKET FOR GLAUCOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. OPTIC NERVE DISORDERS TREATMENT MARKET FOR OPTIC NEURITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. OPTIC NERVE DISORDERS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 10. OPTIC NERVE DISORDERS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. OPTIC NERVE DISORDERS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. OPTIC NERVE DISORDERS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. OPTIC NERVE DISORDERS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANDA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANDA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANDA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. MEXICO OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 30. EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. GERMANY OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 34. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. FRANCE OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 37. UK OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. UK OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. UK OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 40. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 42. ITALY OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 43. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 45. SPAIN OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 48. REST OF EUROPE OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 53. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. JAPAN OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. CHINA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 59. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 62. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 64. AUSTRALIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 65. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 67. SOUTH KOREA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 70. REST OF ASIA-PACIFIC OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 73. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 74. LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. BRAZIL OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SAUDI ARABIA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SOUTH AFRICA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 84. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 86. REST OF LAMEA OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 87. SANTEN PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 88. SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 89. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 90. SANTEN PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 91. SANTEN PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
TABLE 92. ABBVIE INC.: KEY EXECUTIVES
TABLE 93. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 94. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 95. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 96. ABBVIE INC.: KEY STRATERGIES
TABLE 97. NOVARTIS AG: KEY EXECUTIVES
TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 101. NOVARTIS AG: KEY STRATERGIES
TABLE 102. PFIZER, INC.: KEY EXECUTIVES
TABLE 103. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 104. PFIZER, INC.: PRODUCT SEGMENTS
TABLE 105. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 106. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
TABLE 107. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
TABLE 108. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
TABLE 109. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
TABLE 110. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 115. MALLINCKRODT PHARMACEUTICALS: KEY EXECUTIVES
TABLE 116. MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 117. MALLINCKRODT PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 118. MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 119. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 120. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 121. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 122. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 123. .AERIE PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 124. .AERIE PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 125. .AERIE PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 126. .AERIE PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 127. CIPLA LTD: KEY EXECUTIVES
TABLE 128. CIPLA LTD: COMPANY SNAPSHOT
TABLE 129. CIPLA LTD: PRODUCT SEGMENTS
TABLE 130. CIPLA LTD: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 視神経疾患治療のグローバル市場（2022年-2029年）：薬理的、外科的
  • 伝染性軟属腫（MC）治療のグローバル市場2023：凍結療法、免疫調節療法、局所療法
  • 肉腫治療薬のグローバル市場（2021〜2031）：悪性骨腫瘍、軟部肉腫
  • 小児用ワクチンのグローバル市場（2021〜2031）：一価、多価
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC094 )"視神経疾患治療のグローバル市場（2021～2031）：ステロイド療法、免疫調節療法、その他" (英文：Optic Nerve Disorders Treatment Market By Treatment Type (Steroidal Therapy, Immunomodulators therapy, Others), By Indication (Glaucoma, Optic Neuritis, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。